Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Starts & Stops: Neovasc Reports Progress On TIARA-II Trial Of Transcatheter Mitral Valve

Executive Summary

Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Jan. 28 through Feb. 4, including announcements from Neovasc, NaturalCycles Nordic, and Elekta.

You may also be interested in...



Neovasc Maintains Investor Confidence Despite FDA Struggles; Sells $72M In Stock

Despite a recent unfavorable FDA advisory panel for its Reducer coronary sinus device, some investors showed their faith in the Canadian company by buying 36 million shares.

FDA Schedules Advisory Panel To Review Neovasc’s Angina Treatment

The US FDA's Circulatory System Devices Panel will meet on 27 October to evaluate Neovasc’s Reducer device, a minimally invasive treatment for drug-refractory angina.

Results Recap: Neovasc's Tiara TMVR Succeeds In 12 Patients

Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past week, based on information collected by Meddevicetracker. This week's edition covers the week of Oct. 12 - Oct. 18, including trial announcements from PositiveID, Smart Meter, Access Vascular, and Neovasc.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT124595

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel